Herbert J. Conrad

Former President, Roche Pharmaceuticals US

Mr. Conrad has been a director of Celldex since March 2004. He was President of Roche Pharmaceuticals in the United States from 1982 until his retirement in 1993. Mr. Conrad currently serves as Chairman of the Board of Matinas BioPharma Holdings, as a director of Arbutus Biopharmaceuticals and as an advisor to the Seaver Autism Center at Mount Sinai Hospital. He previously served as Chairman of Pharmasset, GenVec and Bone Care International, and he served as a director of Savient Pharmaceuticals and Reliant Pharmaceuticals, where he was a co-founder. Mr. Conrad received B.S. and M.S. degrees from the Brooklyn College of Pharmacy and an honorary doctorate in humane letters from Long Island University.

About us

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.


Our Pipeline